Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jingjing, Zhang, Mingzhi, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784459/
https://www.ncbi.nlm.nih.gov/pubmed/26957112
http://dx.doi.org/10.1186/s13045-016-0250-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784459/
https://www.ncbi.nlm.nih.gov/pubmed/26957112
http://dx.doi.org/10.1186/s13045-016-0250-9

Ejemplares similares